Reversion or compensation of mild cognitive impairment to normal cognition: strategies to prevent the development of Alzheimer’s disease continuum

Marina Avila-Villanueva , Jesús Avila

Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (5) : 392 -400.

PDF (3313KB)
Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (5) :392 -400. DOI: 10.37349/ent.2024.00090
Perspective
research-article
Reversion or compensation of mild cognitive impairment to normal cognition: strategies to prevent the development of Alzheimer’s disease continuum
Author information +
History +
PDF (3313KB)

Abstract

Alzheimer’s disease continuum has been described as the progressive stages of the disease over a long period. This progression can be categorized into three main stages: preclinical, mild cognitive impairment (MCI), and dementia. It has been suggested that there is a bidirectional relationship between the preclinical stage and MCI, but not between dementia and the earlier stages. The stage of MCI should be further analyzed, especially in cases where there is a reversion from MCI to a normal cognitive condition. The mechanisms behind this reversion deserve further investigation to differentiate true reversion from compensatory mechanisms. Analyzing reversion in greater detail could help identify potential therapies aimed at preventing or delaying the onset of dementia. As indicated, the primary focus has been on research indicating that MCI can revert to normal cognition. This reversion can occur by addressing risk factors through lifestyle changes, although a novel mechanism involving a transient functional compensation process in response to cognitive impairment should be also taken into account.

Keywords

Alzheimer’s disease / mild cognitive impairment / reversion / normal cognition

Cite this article

Download citation ▾
Marina Avila-Villanueva, Jesús Avila. Reversion or compensation of mild cognitive impairment to normal cognition: strategies to prevent the development of Alzheimer’s disease continuum. Exploration of Neuroprotective Therapy, 2024, 4 (5) : 392-400 DOI:10.37349/ent.2024.00090

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sharma N, Pasala MS, Prakash A. Mitochondrial DNA: Epigenetics and environment. Environ Mol Mutagen. 2019; 60: 668-82.

[2]

DeCarli C, Maillard P, Pase MP, Beiser AS, Kojis D, Satizabal CL, et al. Trends in Intracranial and Cerebral Volumes of Framingham Heart Study Participants Born 1930 to 1970. JAMA Neurol. 2024; 81: 471-80.

[3]

Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016; 374: 523-32.

[4]

Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al.; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012; 367: 795-804.

[5]

Avila J, Perry G. A Multilevel View of the Development of Alzheimer’s Disease. Neuroscience. 2021; 457: 283-93.

[6]

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 280-92.

[7]

Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017; 9: 60.

[8]

Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, et al.; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019; 15: 888-98.

[9]

Stern Y, Barnes CA, Grady C, Jones RN, Raz N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. Neurobiol Aging. 2019; 83: 124-9.

[10]

Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol. 1985; 42: 1097-105.

[11]

Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: A systematic review and meta-analysis. Neurology. 2020; 94: 436-48.

[12]

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021; 397: 1577-90.

[13]

Libon DJ, Swenson R, Tobyne S, Jannati A, Schulman D, Price CC, et al. Dysexecutive difficulty and subtle everyday functional disabilities: the digital Trail Making Test. Front Neurol. 2024; 15: 1354647.

[14]

Festari C, Massa F, Cotta Ramusino M, Gandolfo F, Nicolosi V, Orini S, et al. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase. Alzheimers Dement. 2023; 19: 1729-41.

[15]

García S, Cuetos F, Novelli A, Martínez C. A new and short protocol to achieve the early diagnosis of mild cognitive impairment. Neurol Sci. 2021; 42: 3687-94.

[16]

Li G, Toschi N, Devanarayan V, Batrla R, Boccato T, Cho M, et al. The age-specific comorbidity burden of mild cognitive impairment: a US claims database study. Alzheimers Res Ther. 2023; 15: 211.

[17]

Mattke S, Jun H, Chen E, Liu Y, Becker A, Wallick C. Expected and diagnosed rates of mild cognitive impairment and dementia in the U. Alzheimers Res Ther. 2023; 15: 128.

[18]

Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001; 58: 397-405.

[19]

Del Ser T, Frades B, Valentí-Soler M, Zea-Sevilla MA, Valeriano-Lorenzo E, Carnero-Pardo C. Discriminant validity and inter-rater concordance of two scoring systems for the clock test. Rev Esp Geriatr Gerontol. 2023; 58: 101404. Spanish.

[20]

Jannati A, Toro-Serey C, Gomes-Osman J, Banks R, Ciesla M, Showalter J, et al. Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia. Alzheimers Res Ther. 2024; 16: 2.

[21]

Jia X, Wang Z, Huang F, Su C, Du W, Jiang H, et al. A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry. 2021; 21: 485.

[22]

Pinto TCC, Machado L, Bulgacov TM, Rodrigues-Júnior AL, Costa MLG, Ximenes RCC, et al. Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) in the elderly? Int Psychogeriatr. 2019; 31: 491-504.

[23]

Liu H, Weakley AM, Zhang J, Liu X. A Transformer Approach for Cognitive Impairment Classification and Prediction. Alzheimer Dis Assoc Disord. 2024; 38: 189-94.

[24]

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256: 183-94.

[25]

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56: 303-8.

[26]

Babiloni C, Jakhar D, Tucci F, Del Percio C, Lopez S, Soricelli A, et al. Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer’s disease mild cognitive impairment progression at a 6-month follow-up. Neurobiol Aging. 2024; 137: 19-37.

[27]

Belleville S, Fouquet C, Hudon C, Zomahoun HTV, Croteau J ; Consortium for the Early Identification of Alzheimer’s disease-Quebec. Neuropsychological Measures that Predict Progression from Mild Cognitive Impairment to Alzheimer’s type dementia in Older Adults: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2017; 27: 328-53.

[28]

Boccardi M, Monsch AU, Ferrari C, Altomare D, Berres M, Bos I, et al.; Consortium for the Harmonization of Neuropsychological Assessment for Neurocognitive Disorders. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimers Dement. 2022; 18: 29-42.

[29]

Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90: 126-35.

[30]

Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013; 3: 320-32.

[31]

McGrattan AM, Pakpahan E, Siervo M, Mohan D, Reidpath DD, Prina M, et al. Risk of conversion from mild cognitive impairment to dementia in low- and middle-income countries: A systematic review and meta-analysis. Alzheimers Dement (N Y). 2022; 8: e12267.

[32]

Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol. 2007; 165: 1231-8.

[33]

McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms. Neurology. 2022; 98: e2132-39.

[34]

Sachdev PS, Lipnicki DM, Crawford J, Reppermund S, Kochan NA, Trollor JN, et al.; Sydney Memory, Ageing Study Team. Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study. PLoS One. 2013; 8: e59649.

[35]

Sanz-Blasco R, Ruiz-Sánchez de León JM, Ávila-Villanueva M, Valentí-Soler M, Gómez-Ramírez J, Fernández-Blázquez MA. Transition from mild cognitive impairment to normal cognition: Determining the predictors of reversion with multi-state Markov models. Alzheimers Dement. 2022; 18: 1177-85.

[36]

Shimada H, Doi T, Lee S, Makizako H. Reversible predictors of reversion from mild cognitive impairment to normal cognition: a 4-year longitudinal study. Alzheimers Res Ther. 2019; 11: 24.

[37]

Wood H. Alzheimer disease: Meta-analysis finds high reversion rate from MCI to normal cognition. Nat Rev Neurol. 2016; 12: 189.

[38]

Canevelli M, Grande G, Lacorte E, Quarchioni E, Cesari M, Mariani C, et al. Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis. J Am Med Dir Assoc. 2016; 17: 943-8.

[39]

Nianogo RA, Rosenwohl-Mack A, Yaffe K, Carrasco A, Hoffmann CM, Barnes DE. Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US. JAMA Neurol. 2022; 79: 584-91.

[40]

Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7: 137-52.

[41]

Debette S, Grond-Ginsbach C, Bodenant M, Kloss M, Engelter S, Metso T, et al.; Cervical Artery Dissection Ischemic Stroke Patients (CADISP) Group. Differential features of carotid and vertebral artery dissections: the CADISP study. Neurology. 2011; 77: 1174-81.

[42]

Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 2013; 4: 640-50.

[43]

Ávila-Villanueva M, Gómez-Ramírez J, Ávila J, Fernández-Blázquez MA. Loneliness as Risk Factor for Alzheimer’s disease. Curr Aging Sci. 2022; 15: 293-96.

[44]

Di Marco LY, Marzo A, Muñoz-Ruiz M, Ikram MA, Kivipelto M, Ruefenacht D, et al. Modifiable lifestyle factors in dementia: a systematic review of longitudinal observational cohort studies. J Alzheimers Dis. 2014; 42: 119-35.

[45]

Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurol. 2004; 3: 246-8.

[46]

Klekociuk SZ, Summers MJ. Lowered performance in working memory and attentional sub-processes are most prominent in multi-domain amnestic mild cognitive impairment subtypes. Psychogeriatrics. 2014; 14: 63-71.

[47]

Feng Y, Kim M, Yao X, Liu K, Long Q, Shen L, et al.; Alzheimer’s Disease Neuroimaging Initiative. Deep multiview learning to identify imaging-driven subtypes in mild cognitive impairment. BMC Bioinformatics. 2022; 23: 402.

[48]

Kang L, Jiang J, Huang J, Zhang T. Identifying Early Mild Cognitive Impairment by Multi-Modality MRI-Based Deep Learning. Front Aging Neurosci. 2020; 12: 206.

[49]

Ryoo HG, Choi H, Shi K, Rominger A, Lee DY, Lee DS, et al.; Alzheimer’s Disease Neuroimaging Initiative. Distinct subtypes of spatial brain metabolism patterns in Alzheimer’s disease identified by deep learning-based FDG PET clusters. Eur J Nucl Med Mol Imaging. 2024; 51: 443-54.

[50]

Tifratene K, Robert P, Metelkina A, Pradier C, Dartigues JF. Progression of mild cognitive impairment to dementia due to AD in clinical settings. Neurology. 2015; 85: 331-8.

[51]

Zuliani G, Polastri M, Romagnoli T, Marabini L, Seripa D, Cervellati C, et al. Clinical and demographic parameters predict the progression from mild cognitive impairment to dementia in elderly patients. Aging Clin Exp Res. 2021; 33: 1895-902.

[52]

Csukly G, Sirály E, Fodor Z, Horváth A, Salacz P, Hidasi Z, et al. The Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI. Front Aging Neurosci. 2016; 8: 52.

[53]

Roberts RO, Knopman DS, Mielke MM, Cha RH, Pankratz VS, Christianson TJ, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014; 82: 317-25.

[54]

Li H, Fan X, Li K, Zhang C, Jia X. Increased anterior insula connectivity associated with cognitive maintenance in amnestic mild cognitive impairment: a longitudinal study. Brain Imaging Behav. 2024.

[55]

Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15: 673-84.

[56]

Watve M, Keskar Sardeshmukh A. “Vitaction” deficiency: a possible root cause for multiple lifestyle disorders including Alzheimer’s disease. Explor Neuroprot Ther. 2024; 4: 108-18.

[57]

Franco R. Vitactions: vitamins for the brain. Explor Neuroprot Ther. 2024; 4: 300-7.

[58]

Sun X, Jin L, Ling P. Review of drugs for Alzheimer’s disease. Drug Discov Ther. 2012; 6: 285-90.

[59]

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023; 388: 9-21.

[60]

Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease. Neurotherapeutics. 2023; 20: 195-206.

PDF (3313KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉